News & Events
Published On: 11/10/2016
TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World Data
CHAPEL HILL, NC – (November 10, 2016) – TARGET PharmaSolutions, Inc., a clinical data company focused on real world evidence, is pleased to announce two new collaborations with Bristol-Myers Squibb (BMY) to advance the understanding of treatment patterns in nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The TARGET model provides pharmaceutical and biotechnology partners access to a robust disease state registry that is also linked to a biorepository and patient reported outcomes, providing unique data and insights compared to typical patient registries.
“The unique collaboration with Bristol-Myers Squibb across both NASH and HCC will ensure that we are able to further provide the hepatology and oncology community with important insights across multiple conditions affecting the liver, especially as these conditions continue to develop into growing public health issues,” said Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions. The impact of the TARGET platform will help pharmaceutical partners better understand multiple elements of disease etiology, treatment modalities, and outcomes.
TARGET-NASH’s first patient enrollment occurred August 1, 2016. The company plans on enrolling up to 15,000 patients, at up to 100 sites worldwide. TARGET-HCC’s first patient enrollment is set for Q4 2016. The company plans on enrolling up to 5,000 patients worldwide, at up to 75 sites in the US and Europe.
TARGET PharmaSolutions was formed in February 2015 and currently has four disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD (inflammatory bowel disease). The TARGET model is based on the success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011 by Drs. Michael Fried, MD (University of North Carolina) and David Nelson, MD (University of Florida), HCV-TARGET has enrolled over 10,000 patients and has generated data that has been used by physicians, payers, and regulatory agencies around the world.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
09/24/2020TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid Use
09/09/2020Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH Study
09/01/2020EASL 2020: TARGET-NASH Oral Presentation & Abstract Poster Recap
08/28/2020Target RWE Builds Growing COVID-19 Data Set of 70,000+ Patients, Announces Published Data Findings
08/24/2020TARGET-NASH Expands to Europe, Enrolls First Participant